T. Rowe Price Investment Management, Inc. Immunovant, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 5,117,234 shares of IMVT stock, worth $141 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
5,117,234
Previous 3,331,017
53.62%
Holding current value
$141 Million
Previous $95 Million
33.47%
% of portfolio
0.08%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding IMVT
# of Institutions
218Shares Held
67.1MCall Options Held
2.48MPut Options Held
561K-
Vanguard Group Inc Valley Forge, PA6.68MShares$184 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$165 Million7.27% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY3.87MShares$106 Million1.5% of portfolio
-
State Street Corp Boston, MA2.7MShares$74.2 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...